Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
- M. Mirza, B. Monk, +25 authors U. Matulonis
- The New England journal of medicine
- 7 October 2016
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. Expand
A phase 3 trial of bevacizumab in ovarian cancer.
In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer. Expand
Rethinking ovarian cancer: recommendations for improving outcomes
Nine major recommendations that should be taken to improve the outcome for women with ovarian cancer are outlined in this Opinion article. Expand
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
The study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed. Expand
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
The ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor, was assessed in ARIEL2, an international, multicentre, two-part, phase 2, open-label study. Expand
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- K. Moore, N. Colombo, +18 authors P. DiSilvestro
- The New England journal of medicine
- 21 October 2018
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo. Expand
The statins as anticancer agents.
- Kelvin K. W. Chan, A. Oza, L. Siu
- Biology, Medicine
- Clinical cancer research : an official journal of…
Potential future directions in the development of the statins as anticancer agents include combinations with chemotherapeutic or other molecular-targeted agents, combinations with radiotherapy, maintenance therapy in minimal disease status, and as chemopreventive therapy. Expand
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. Expand
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3…
- É. Pujade-Lauraine, J. Ledermann, +17 authors P. Pautier
- The Lancet. Oncology
- 1 September 2017
Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Expand
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Although the difference in quality of life was non-significant at the primary endpoint, this trial shows promising findings that support early palliative care for patients with advanced cancer. Expand